UCB SA (UCBJY)

Market Cap	57.43B
Revenue (ttm)	8.04B +25.6%
Net Income	1.56B +455.0%
EPS	8.06 +462.0%
Shares Out	n/a
PE Ratio	36.71
Forward PE	27.58
Dividend	0.48 (0.31%)
Ex-Dividend Date	Apr 28, 2025

Volume	29,500
Average Volume	31,516
Open	150.82
Previous Close	157.32
Day's Range	150.07 - 151.22
52-Week Range	71.16 - 157.44
Beta	0.25
RSI	56.27
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1925
• Employees: 8,600
• Stock Exchange: OTCMKTS
• Ticker Symbol: UCBJY

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial numbers in EUR